BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 25822435)

  • 1. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.
    Ogawa Y; Honda Y; Kessoku T; Tomeno W; Imajo K; Yoneda M; Kawanaka M; Kirikoshi H; Ono M; Taguri M; Saito S; Yamanaka T; Wada K; Nakajima A
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1795-1803. PubMed ID: 29633352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study.
    El-Mezayen HA; Habib S; Marzok HF; Saad MH
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):378-85. PubMed ID: 25874509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
    Cengiz M; Ozenirler S; Kocabiyik M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibro-Mark: a panel of laboratory parameters for predicting significant fibrosis in chronic hepatitis C patients.
    Attallah AM; Omran D; Omran MM; Albannan MS; Zayed RA; Saif S; Farid A; Hassany M; Yosry A
    Br J Biomed Sci; 2018 Jan; 75(1):19-23. PubMed ID: 28945150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
    Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
    Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Kumagai E; Mano Y; Yoshio S; Shoji H; Sugiyama M; Korenaga M; Ishida T; Arai T; Itokawa N; Atsukawa M; Hyogo H; Chayama K; Ohashi T; Ito K; Yoneda M; Kawaguchi T; Torimura T; Nozaki Y; Watanabe S; Mizokami M; Kanto T
    Sci Rep; 2016 Oct; 6():35282. PubMed ID: 27739482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The diagnostic value of serum hyaluronic acid, 7S domain of type IV collagen and AST/ALT ratio as markers of hepatic fibrosis in chronic hepatitis B and cirrhosis patients].
    Park JH; Park CK; Kim ES; Park SY; Jo CM; Tak WY; Kweon YO; Kim SK; Choi YW
    Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):79-88. PubMed ID: 12824747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis.
    Rossi E; Adams LA; Ching HL; Bulsara M; MacQuillan GC; Jeffrey GP
    Clin Chem Lab Med; 2013 May; 51(5):1107-14. PubMed ID: 23152415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic significance of type IV collagen and hyaluronic acid in the serum of patients with chronic hepatitis C for staging hepatic fibrosis].
    Iushchuk ND; Znoĭko OO; Safiullina NKh; Dudina KR; Kelli EI; Klimova EA; Kashirin VI; Braginskiĭ DM; Kushlinskiĭ NE; Liubimova NV; Vasilev AIu; Penkina TV; Danilin AG
    Ter Arkh; 2005; 77(4):50-5. PubMed ID: 15938533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Suzuki A; Angulo P; Lymp J; Li D; Satomura S; Lindor K
    Liver Int; 2005 Aug; 25(4):779-86. PubMed ID: 15998429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan.
    Kawamura Y; Ikeda K; Arase Y; Sorin Y; Fukushima T; Kunimoto H; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
    Hepatol Int; 2015 Apr; 9(2):269-77. PubMed ID: 25788193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.